HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ming Xu Selected Research

CPU0213

1/2016Inhibition of CPU0213, a Dual Endothelin Receptor Antagonist, on Apoptosis via Nox4-Dependent ROS in HK-2 Cells.
1/2009Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats.
6/2008Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ming Xu Research Topics

Disease

162Neoplasms (Cancer)
09/2022 - 11/2005
41Inflammation (Inflammations)
07/2022 - 01/2012
35Neoplasm Metastasis (Metastasis)
05/2022 - 11/2005
33Breast Neoplasms (Breast Cancer)
03/2022 - 02/2009
22Reperfusion Injury
05/2022 - 12/2006
22Hepatocellular Carcinoma (Hepatoma)
01/2022 - 07/2004
22Infections
01/2022 - 11/2004
20Colorectal Neoplasms (Colorectal Cancer)
08/2021 - 11/2005
20Fibrosis (Cirrhosis)
02/2021 - 08/2010
19Ischemia
01/2022 - 02/2005
19Carcinogenesis
12/2021 - 01/2002
18Osteosarcoma (Osteogenic Sarcoma)
05/2021 - 08/2009
15Wounds and Injuries (Trauma)
06/2022 - 05/2009
14Hypertrophy
04/2022 - 12/2005
14Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 03/2017
14Heart Failure
01/2021 - 04/2007
12Cardiomegaly (Heart Hypertrophy)
04/2022 - 01/2009
11Hemorrhage
11/2022 - 02/2008
11Cardiovascular Diseases (Cardiovascular Disease)
04/2022 - 10/2011
11Lung Neoplasms (Lung Cancer)
01/2022 - 03/2013
10Insulin Resistance
01/2022 - 02/2003
10Myocardial Infarction
01/2022 - 01/2009
10Obesity
09/2021 - 09/2010
9Hypoxia (Hypoxemia)
12/2021 - 10/2008
9Coronary Artery Disease (Coronary Atherosclerosis)
07/2018 - 03/2004
8COVID-19
01/2022 - 05/2020
8Atherosclerosis
01/2022 - 09/2010
8Body Weight (Weight, Body)
11/2020 - 02/2003
8Pancreatic Neoplasms (Pancreatic Cancer)
01/2018 - 04/2008
7Necrosis
01/2022 - 07/2012
7Chronic Obstructive Pulmonary Disease (COPD)
07/2021 - 06/2012
7Lymphatic Metastasis
01/2021 - 11/2005
7Substance-Related Disorders (Drug Abuse)
06/2013 - 06/2002
6Liver Neoplasms (Liver Cancer)
09/2022 - 01/2012
6Lung Injury
02/2022 - 02/2005
6Hypertension (High Blood Pressure)
01/2022 - 02/2009
6Stroke (Strokes)
12/2021 - 07/2009
6Stomach Neoplasms (Stomach Cancer)
10/2021 - 01/2013
6Type 2 Diabetes Mellitus (MODY)
05/2021 - 05/2004
6Colonic Neoplasms (Colon Cancer)
02/2021 - 01/2017
6Acute Kidney Injury (Acute Renal Failure)
01/2021 - 07/2009
6Schistosomiasis (Bilharziasis)
06/2015 - 08/2002
6Heart Diseases (Heart Disease)
08/2012 - 03/2010
5Triple Negative Breast Neoplasms
03/2022 - 01/2017
5Adenocarcinoma of Lung
12/2021 - 01/2017
5Glioblastoma (Glioblastoma Multiforme)
06/2020 - 01/2014

Drug/Important Bio-Agent (IBA)

59Proteins (Proteins, Gene)FDA Link
04/2022 - 01/2004
39Biomarkers (Surrogate Marker)IBA
01/2022 - 08/2010
31Pharmaceutical PreparationsIBA
09/2022 - 09/2004
21Biological ProductsIBA
10/2021 - 01/2012
20MicroRNAs (MicroRNA)IBA
01/2022 - 10/2011
18Messenger RNA (mRNA)IBA
12/2021 - 07/2012
15Small Interfering RNA (siRNA)IBA
02/2020 - 01/2012
14Therapeutic UsesIBA
04/2022 - 02/2014
14Peptides (Polypeptides)IBA
10/2021 - 01/2014
12Long Noncoding RNAIBA
01/2022 - 08/2014
10CytokinesIBA
07/2021 - 02/2005
10Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 11/2014
9LipopolysaccharidesIBA
07/2022 - 01/2013
9Interleukin-6 (Interleukin 6)IBA
01/2022 - 12/2005
9EnzymesIBA
07/2021 - 01/2016
9AntigensIBA
04/2021 - 01/2002
9Caspase 3 (Caspase-3)IBA
10/2020 - 05/2013
9Glucose (Dextrose)FDA LinkGeneric
01/2020 - 02/2003
8RNA (Ribonucleic Acid)IBA
01/2022 - 01/2002
8Cisplatin (Platino)FDA LinkGeneric
01/2021 - 08/2013
8AcidsIBA
05/2020 - 01/2012
8Angiotensin IIIBA
01/2020 - 01/2008
7InflammasomesIBA
01/2022 - 05/2014
7Phosphotransferases (Kinase)IBA
01/2022 - 03/2013
7Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2020 - 09/2008
7CollagenIBA
01/2020 - 08/2010
6Streptozocin (Streptozotocin)FDA Link
01/2021 - 02/2003
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2019 - 09/2008
6ErythropoietinFDA Link
01/2019 - 02/2005
5AntagomirsIBA
07/2022 - 02/2013
5stachydrineIBA
01/2022 - 01/2017
5SenotherapeuticsIBA
01/2022 - 01/2019
5DNA (Deoxyribonucleic Acid)IBA
01/2022 - 01/2013
5salicylhydroxamic acid (SHAM)IBA
11/2021 - 03/2013
5p38 Mitogen-Activated Protein KinasesIBA
10/2021 - 07/2004
5Reactive Oxygen Species (Oxygen Radicals)IBA
10/2021 - 05/2004
5Adrenergic Receptors (Adrenergic Receptor)IBA
01/2021 - 06/2008
5Isoproterenol (Isoprenaline)FDA LinkGeneric
01/2021 - 06/2008
5CeramidesIBA
11/2020 - 01/2012
5Atrial Natriuretic Factor (ANF)IBA
09/2020 - 10/2008

Therapy/Procedure

63Therapeutics
05/2022 - 11/2004
25Drug Therapy (Chemotherapy)
01/2022 - 09/2005
14Kidney Transplantation
01/2022 - 01/2011
13Radiofrequency Ablation
01/2022 - 01/2012
8Length of Stay
01/2022 - 12/2008
8Craniotomy
01/2022 - 10/2012
8Aftercare (After-Treatment)
01/2022 - 11/2003
8Limb Salvage
05/2021 - 08/2009
7Immunotherapy
01/2022 - 02/2014
7Transplantation
01/2022 - 08/2009
7Prostheses and Implants (Prosthesis)
06/2019 - 08/2010
5Lasers (Laser)
01/2022 - 07/2012
5Radiotherapy
12/2021 - 09/2005
5Replantation
05/2021 - 02/2012